# Parkinson Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/parkinson-disease

> 6 upcoming FDA catalysts in Parkinson Disease: biib122 225 mg (DNLI) on March 2027 (primary completion); biib122 225 mg (DNLI) on Mar to Jun 2027 (topline data readout); bhv-8000 10mg (BHVN) on August 2027 (primary completion); bhv-8000 10mg (BHVN) on Aug to Nov 2027 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 28, 2025 | [Lenrispodun primary completion](https://sec-api.dev/pdufa/lenrispodun) | JNJ | Parkinson Disease | completed | "NCT05766813 (Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-28 (ACTUAL); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05766813)) |
| December 1, 2025 | [Juvmo (tavapadon) primary completion](https://sec-api.dev/pdufa/tavapadon) | ABBV | Parkinson Disease | completed | "NCT04760769 (Open-label Trial in Parkinson's Disease (PD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04760769)) |
| March 9, 2026 | [Biib122 225 mg primary completion](https://sec-api.dev/pdufa/biib122) | BIIB | Parkinson Disease | completed | "NCT05348785 (A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348785)) |
| March 2027 | [Biib122 225 mg primary completion](https://sec-api.dev/pdufa/biib122) | DNLI | Parkinson Disease | scheduled | "NCT06602193 (Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602193)) |
| Mar to Jun 2027 | [Biib122 225 mg topline data readout](https://sec-api.dev/pdufa/biib122) | DNLI | Parkinson Disease | scheduled | "NCT06602193 (Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Denali Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602193)) |
| August 2027 | [Bhv-8000 10mg primary completion](https://sec-api.dev/pdufa/bhv-8000) | BHVN | Parkinson Disease | scheduled | "NCT06976268 (A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976268)) |
| Aug to Nov 2027 | [Bhv-8000 10mg topline data readout](https://sec-api.dev/pdufa/bhv-8000) | BHVN | Parkinson Disease | scheduled | "NCT06976268 (A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06976268)) |
| Jun to Sep 2028 | [Low dose gt-02287 topline data readout](https://sec-api.dev/pdufa/low-dose-gt-02287) | GANX | Parkinson Disease | scheduled | "NCT07280299 (Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Gain Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280299)) |
| June 2028 | [Low dose gt-02287 primary completion](https://sec-api.dev/pdufa/low-dose-gt-02287) | GANX | Parkinson Disease | scheduled | "NCT07280299 (Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Gain Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07280299)) |

## Drugs

- [Lenrispodun](https://sec-api.dev/pdufa/lenrispodun) (JNJ)
- [Juvmo (tavapadon)](https://sec-api.dev/pdufa/tavapadon) (ABBV)
- [Biib122 225 mg](https://sec-api.dev/pdufa/biib122) (BIIB)
- [Bhv-8000 10mg](https://sec-api.dev/pdufa/bhv-8000) (BHVN)
- [Low dose gt-02287](https://sec-api.dev/pdufa/low-dose-gt-02287) (GANX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/parkinson-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Parkinson Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/parkinson-disease

```bibtex
@misc{secapidev_indications_parkinson_disease_20261116,
  title        = {Parkinson Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/parkinson-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_parkinson_disease_20261116","title":"Parkinson Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/parkinson-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
